{
  "retracted": false,
  "timestamp": 1504224000000,
  "updates": [
    {
      "timestamp": 1550491955839,
      "identifier": {
        "doi": "10.1212/nxi.0000000000000391"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1212/nxi.0000000000000360"
  },
  "journal": "Neurology - Neuroimmunology Neuroinflammation",
  "publisher": "Ovid Technologies (Wolters Kluwer Health)",
  "title": "Both cladribine and alemtuzumab may effect MS via B-cell depletion"
}
